Condition: Bipolar Disorder · Bipolar Depression · Bipolar I Disorder · Sponsor: Xenon Pharmaceuticals Inc.
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).
This description comes directly from the study's public registry record.
Xenon Medical Affairs · 1-604-484-3300 · XenonCares@xenon-pharma.com
Always discuss trial participation with your own doctor first.
| Noble Clinical Research | Tucson, Arizona, United States | Recruiting |
| Woodland International Research Group | Little Rock, Arkansas, United States | Recruiting |
| Woodland Research Northwest | Rogers, Arkansas, United States | Recruiting |
| Clinical Innovations Inc | Bellflower, California, United States | Recruiting |
| ProScience Research Group | Culver City, California, United States | Recruiting |
| ATP Clinical Research | Orange, California, United States | Recruiting |
| NRC Research Institute | Orange, California, United States | Recruiting |
| Clinical Innovations Inc | Riverside, California, United States | Recruiting |
| PharmaSouth Research, LLC | Coral Gables, Florida, United States | Recruiting |
| Clinical Neuroscience Solutions, Inc. | Jacksonville, Florida, United States | Recruiting |
| Central Miami Medical Institute | Miami, Florida, United States | Recruiting |
| Clinical Neuroscience Solutions, Inc | Orlando, Florida, United States | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07172516